<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02016235</url>
  </required_header>
  <id_info>
    <org_study_id>13-004774</org_study_id>
    <nct_id>NCT02016235</nct_id>
  </id_info>
  <brief_title>Role Of Phosphorus And FGF 23 In Patients With Dent Disease</brief_title>
  <official_title>Role Of Phosphorus And FGF 23 In Patients With Dent Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Dent disease have suppressed levels of FGF 23 which contributes to
      hypercalciuria, kidney stones, nephrocalcinosis and renal failure. Supplementation with
      phosphorus may reduce hypercalciuria.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 24 hr urine and serum after 2 weeks of phosphorus supplementation</measure>
    <time_frame>6 months</time_frame>
    <description>This study will measure the changes in a 24 hr urine supersaturation and serum after phosphorus is taken for two weeks to decrease stone formation</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Dent Disease</condition>
  <arm_group>
    <arm_group_label>Dent Disease patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A. 1. LMWP (at least 5 times above the upper limit of normal) and at least 1 of the following criteria: 1. Hypercalriuria, 2. Kidney Stones, 3. Nephrocalcinosis, 4. Hypophosphatemia, 5. Renal phosphate leak, 6. Aminoaciduria, 7. Glucosuria without diabetes mellitus, 8. Hematuria, 9. Renal insufficiency, 10. Family history with X-linked inheritance or B. 1 of the above criteria (1-9) and confirmed genetic mutation of CLCN5 or OCRL1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypercalciuria w/ phosphate leak</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A. Male patients &gt;18 years old will be recruited from the stone clinics at Mayo Clinic and NY Harbor VA Medical Center B. Eligibility Criteria include: 1) History of a symptomatic calcium oxalate or calcium phosphate stone; 2) hypercalciuria (&gt;250 mg/24 hrs); 3) renal phosphate leak (TMP/GFR &lt;2.07 mg/dl)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypercalciuria w/out phosphate leak</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A. Male patients &gt;18 years old will be recruited from the stone clinics at Mayo Clinic and NY Harbor VA Medical Center B. Eligibility Criteria include: 1) History of a symptomatic calcium oxalate or calcium phosphate stone; 2) hypercalciuria (&gt;250 mg/24 hrs); 3) (TMP/GFR &lt;2.07 mg/dl)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phosphorus Supplement</intervention_name>
    <description>250 mg po qid</description>
    <arm_group_label>Dent Disease patients</arm_group_label>
    <arm_group_label>hypercalciuria w/ phosphate leak</arm_group_label>
    <arm_group_label>hypercalciuria w/out phosphate leak</arm_group_label>
    <other_name>K-phos neutral</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients will be recruited from those in the RKSC Dent Registry

             Diagnostic criteria for Dent disease include:

             A. 1. LMWP (at least 5 times above the upper limit of normal) and at least 1 of the
             following criteria: 1. Hypercalciuria, 2. Kidney stones, 3. Nephrocalcinosis, 4.
             Hypophosphatemia, 5. Renal phosphate leak, 6. Aminoaciduria, 7. Glucosuria without
             diabetes mellitus, 8. Hematuria, 9. Renal insufficiency, 10. Family history with
             x-linked inheritance or B. 1 of the above criteria (1-9) and confirmed genetic
             mutation of CLCN5 or OCRL1.

          2. Idiopathic calcium nephrolithiasis with renal phosphate leak

               1. Male patients &gt; 18 years old

               2. History of symptomatic calcium oxalate or calcium phosphate stone, hypercalciuria
                  (&gt;250 mg/24 hrs), renal phosphate leak (TMP/GFR &lt;2.07 mg/dl)

          3. Idiopathic calcium nephrolithiasis without renal phosphate leak

               1. Male patients &gt; 18 years old

               2. History of symptomatic calcium oxalate or calcium phosphate stone, hypercalciuria
                  (&gt;250 mg/24 hrs), renal phosphate leak (TMP/GFR &lt;2.07 mg/dl)

        Exclusion Criteria:

          1. Exclusion for Dent disease include: primary or secondary hyperparathyroidism,
             hyperthyroidism, chronic diarrhea states; intake of thiazide diuretics,
             glucocorticoids, or estrogens within one month of the study.

          2. Exclusion criteria for calcium stone formers include: primary or secondary
             hyperparathyroidism, hyperthyroidism, estimated GFR &lt;40 ml/mn/1.73m2, chronic diarrhea
             states; intake of thiazide diuretics, glucocorticoids, or estrogens within one month
             of the study.

          3. Exclusion criteria include history of symptomatic or asymptomatic kidney stone
             disease; primary or secondary hyperparathyroidism; estimated GFR &lt;40 ml/min/1.73m2,
             chronic diarrhea states; intake of thiazide diuretics, glucocorticoids, or estrogens
             within one month of the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John C Lieske, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara M Seide</last_name>
    <phone>800-270-4637</phone>
    <email>rarekidneystones@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alicia M Meek</last_name>
    <phone>800-270-4637</phone>
    <email>rarekidneystones@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Siede</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara M Seide</last_name>
      <phone>800-270-4637</phone>
      <email>rarekidneystones@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alicia M Meek</last_name>
      <phone>800-270-4637</phone>
      <email>rarekidneystones@mayo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2013</study_first_submitted>
  <study_first_submitted_qc>December 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2013</study_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>John Lieske</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Dent</keyword>
  <keyword>Dents</keyword>
  <keyword>Dent Disease</keyword>
  <keyword>Phosphorus Supplements</keyword>
  <keyword>FGF 23</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dent Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

